Carmell Therapeutics raises $4m for regenerative biomaterial

Carnegie Mellon spin-out Carmell Therapeutics said today that it closed a $4 million Series B financing round last month that it plans to use to bring its first product candidate to Phase III clinical development.

Its Bone Healing Accelerant uses pooled plasma to boost the healing of bone and soft tissues. Current investors, including Pittsburgh Life Sciences Greenhouse and Harbor Light Capital, participated and Keiretsu Forum Capital, a new investor, also joined the round.

Get the full story at our sister site, Drug Delivery Business News.

The post Carmell Therapeutics raises $4m for regenerative biomaterial appeared first on MassDevice.

from MassDevice http://ift.tt/2ufffNg